Bide Pharmatech (688073) 주식 개요비데 파마텍은 중국에서 의약품의 연구, 개발, 생산 및 판매에 종사하는 회사입니다. 자세히 보기688073 펀더멘털 분석스노우플레이크 점수가치 평가1/6미래 성장0/6과거 실적5/6재무 건전성5/6배당2/6강점주가수익률(36.7x)이 CN 시장(41.6x)보다 낮습니다.지난 1년간 수익이 37.6% 증가했습니다.위험 분석지난 3개월 동안 주가 변동성이 CN 시장과 비교해 높았습니다.1.62% 의 배당금은 잉여현금흐름으로 잘 충당되지 않습니다.모든 위험 점검 보기688073 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW465,688 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA465,688 investors already sharing narrativesYour Fair ValueCN¥Current PriceCN¥71.6035.6% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-14m1b2016201920222025202620282031Revenue CN¥1.4bEarnings CN¥167.9mAdvancedSet Fair ValueView all narrativesBide Pharmatech Co., Ltd. 경쟁사Zhejiang Tianyu PharmaceuticalSymbol: SZSE:300702Market cap: CN¥7.6bSuzhou Highfine BiotechSymbol: SZSE:301393Market cap: CN¥7.0bHunan Jiudian PharmaceuticalSymbol: SZSE:300705Market cap: CN¥5.7bChina Animal Husbandry IndustrySymbol: SHSE:600195Market cap: CN¥6.9b가격 이력 및 성과Bide Pharmatech 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가CN¥71.6052주 최고가CN¥88.8852주 최저가CN¥43.21베타0.541개월 변동45.06%3개월 변동29.24%1년 변동10.97%3년 변동n/a5년 변동n/aIPO 이후 변동11.41%최근 뉴스 및 업데이트Valuation Update With 7 Day Price Move • Aug 07Investor sentiment improves as stock rises 30%After last week's 30% share price gain to CN¥61.60, the stock trades at a trailing P/E ratio of 31.6x. Average trailing P/E is 33x in the Pharmaceuticals industry in China. Total returns to shareholders of 11% over the past year.Valuation Update With 7 Day Price Move • Jul 15Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥57.43, the stock trades at a trailing P/E ratio of 29.5x. Average trailing P/E is 35x in the Pharmaceuticals industry in China. Total loss to shareholders of 1.8% over the past year.공고 • Jun 30Bide Pharmatech Co., Ltd. to Report First Half, 2026 Results on Aug 28, 2026Bide Pharmatech Co., Ltd. announced that they will report first half, 2026 results on Aug 28, 2026Valuation Update With 7 Day Price Move • Jun 29Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥54.24, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total loss to shareholders of 4.1% over the past year.Declared Dividend • Jun 06Dividend of CN¥1.16 announcedShareholders will receive a dividend of CN¥1.16. Ex-date: 10th June 2026 Payment date: 10th June 2026 Dividend yield will be 2.4%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is covered by earnings (59% earnings payout ratio) but not covered by cash flows (281% cash payout ratio). The dividend has increased by an average of 1.8% per year over the past 3 years and payments have been stable during that time. EPS is expected to grow by 32% over the next year, which should provide support to the dividend and adequate earnings cover.Board Change • May 20High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. R&D Director and Supervisor Ronghao Li is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.더 많은 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • Aug 07Investor sentiment improves as stock rises 30%After last week's 30% share price gain to CN¥61.60, the stock trades at a trailing P/E ratio of 31.6x. Average trailing P/E is 33x in the Pharmaceuticals industry in China. Total returns to shareholders of 11% over the past year.Valuation Update With 7 Day Price Move • Jul 15Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥57.43, the stock trades at a trailing P/E ratio of 29.5x. Average trailing P/E is 35x in the Pharmaceuticals industry in China. Total loss to shareholders of 1.8% over the past year.공고 • Jun 30Bide Pharmatech Co., Ltd. to Report First Half, 2026 Results on Aug 28, 2026Bide Pharmatech Co., Ltd. announced that they will report first half, 2026 results on Aug 28, 2026Valuation Update With 7 Day Price Move • Jun 29Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥54.24, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total loss to shareholders of 4.1% over the past year.Declared Dividend • Jun 06Dividend of CN¥1.16 announcedShareholders will receive a dividend of CN¥1.16. Ex-date: 10th June 2026 Payment date: 10th June 2026 Dividend yield will be 2.4%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is covered by earnings (59% earnings payout ratio) but not covered by cash flows (281% cash payout ratio). The dividend has increased by an average of 1.8% per year over the past 3 years and payments have been stable during that time. EPS is expected to grow by 32% over the next year, which should provide support to the dividend and adequate earnings cover.Board Change • May 20High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. R&D Director and Supervisor Ronghao Li is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공고 • Apr 23Bide Pharmatech Co., Ltd., Annual General Meeting, May 13, 2026Bide Pharmatech Co., Ltd., Annual General Meeting, May 13, 2026, at 09:30 China Standard Time. Location: 6F, Building 3, No. 999, Xiangyin Road, Yangpu District, Shanghai China공고 • Mar 30Bide Pharmatech Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026Bide Pharmatech Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026공고 • Dec 26Bide Pharmatech Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026Bide Pharmatech Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026공고 • Sep 30Bide Pharmatech Co., Ltd. to Report Q3, 2025 Results on Oct 30, 2025Bide Pharmatech Co., Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025공고 • Jun 30Bide Pharmatech Co., Ltd. to Report First Half, 2025 Results on Aug 22, 2025Bide Pharmatech Co., Ltd. announced that they will report first half, 2025 results on Aug 22, 2025공고 • Apr 24Bide Pharmatech Co., Ltd., Annual General Meeting, May 14, 2025Bide Pharmatech Co., Ltd., Annual General Meeting, May 14, 2025, at 14:30 China Standard Time. Location: 6F, Building 3, No. 999, Xiangyin Road, Yangpu District, Shanghai China공고 • Mar 28Bide Pharmatech Co., Ltd. to Report Q1, 2025 Results on Apr 24, 2025Bide Pharmatech Co., Ltd. announced that they will report Q1, 2025 results on Apr 24, 2025공고 • Feb 10Bide Pharmatech Co., Ltd. (SHSE:688073) announces an Equity Buyback for CNY 100 million worth of its shares.Bide Pharmatech Co., Ltd. (SHSE:688073) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The shares will be purchased at a price not exceeding CNY 72.30 per share. The purpose of the program is to improve the company's long-term incentive mechanism, fully mobilize the enthusiasm of the employees, and jointly promote the company's long-term development. The repurchased shares will be used for employee stock ownership plans or equity incentive plans, otherwise will be cancelled if the company fails to transfer them within the time limit stipulated by relevant laws and regulations. The program will be funded from company's own funds and special loans. The program will be valid for 6 months.공고 • Jan 22Bide Pharmatech Co., Ltd. (SHSE:688073) agreed to acquire an unknown minority stake in Zhuhai Weibo Investment Co., Ltd. from Vivo (Suzhou) Health Industry Investment Fund (Limited Partnership) managed by Vivo Capital, LLC and Vivo Equity Investment Management (Shanghai) Co. Ltd.Bide Pharmatech Co., Ltd. (SHSE:688073) agreed to acquire an unknown minority stake in Zhuhai Weibo Investment Co., Ltd. from Vivo (Suzhou) Health Industry Investment Fund (Limited Partnership) managed by Vivo Capital, LLC and Vivo Equity Investment Management (Shanghai) Co. Ltd. on January 21, 2025. The consideration consists of common equity of Bide Pharmatech Co., Ltd. to be issued for common equity of Zhuhai Weibo Investment Co., Ltd. As part of consideration, an undisclosed value is paid towards common equity of Zhuhai Weibo Investment Co., Ltd.공고 • Dec 27Bide Pharmatech Co., Ltd. to Report Fiscal Year 2024 Results on Apr 24, 2025Bide Pharmatech Co., Ltd. announced that they will report fiscal year 2024 results on Apr 24, 2025Valuation Update With 7 Day Price Move • Nov 05Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥42.00, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 18x in the Pharmaceuticals industry in China.Reported Earnings • Oct 24Third quarter 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.33 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.36 (up from CN¥0.33 in 3Q 2023). Revenue: CN¥279.2m (down 1.1% from 3Q 2023). Net income: CN¥32.0m (up 8.2% from 3Q 2023). Profit margin: 12% (up from 11% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China.Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to CN¥33.82, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Simply Wall St's valuation model estimates the intrinsic value at CN¥44.40 per share.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 28%After last week's 28% share price gain to CN¥37.43, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Simply Wall St's valuation model estimates the intrinsic value at CN¥43.54 per share.공고 • Sep 30Bide Pharmatech Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024Bide Pharmatech Co., Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024Reported Earnings • Aug 29Second quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.51 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.29 (down from CN¥0.51 in 2Q 2023). Revenue: CN¥269.5m (flat on 2Q 2023). Net income: CN¥25.8m (down 45% from 2Q 2023). Profit margin: 9.6% (down from 17% in 2Q 2023). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China.공고 • Jun 29Bide Pharmatech Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024Bide Pharmatech Co., Ltd. announced that they will report first half, 2024 results on Aug 29, 2024공고 • May 15Bide Pharmatech Co., Ltd., Annual General Meeting, Jun 03, 2024Bide Pharmatech Co., Ltd., Annual General Meeting, Jun 03, 2024, at 14:30 China Standard Time. Location: 6F, Building 3, No. 999, Xiangyin Road, Yangpu District, Shanghai ChinaReported Earnings • Apr 27First quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.41 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.29 (down from CN¥0.41 in 1Q 2023). Revenue: CN¥262.7m (up 4.0% from 1Q 2023). Net income: CN¥26.1m (down 29% from 1Q 2023). Profit margin: 9.9% (down from 15% in 1Q 2023). Revenue is forecast to grow 33% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China.공고 • Mar 29Bide Pharmatech Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024Bide Pharmatech Co., Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024Valuation Update With 7 Day Price Move • Mar 27Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥36.16, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 18x in the Pharmaceuticals industry in China.Reported Earnings • Feb 03Full year 2023 earnings released: EPS: CN¥1.24 (vs CN¥1.98 in FY 2022)Full year 2023 results: EPS: CN¥1.24 (down from CN¥1.98 in FY 2022). Revenue: CN¥1.09b (up 31% from FY 2022). Net income: CN¥113.0m (down 23% from FY 2022). Profit margin: 10% (down from 18% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China.Valuation Update With 7 Day Price Move • Feb 01Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to CN¥39.88, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 16x in the Pharmaceuticals industry in China.공고 • Dec 30Bide Pharmatech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024Bide Pharmatech Co., Ltd. announced that they will report fiscal year 2023 results on Apr 26, 2024Board Change • Nov 17Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Meng Zhang was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.주주 수익률688073CN PharmaceuticalsCN 시장7D-14.1%-4.0%-1.5%1Y11.0%-19.1%4.0%전체 주주 수익률 보기수익률 대 산업: 688073은 지난 1년 동안 -19.1%의 수익을 기록한 CN Pharmaceuticals 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: 688073은 지난 1년 동안 4%를 기록한 CN 시장보다 더 좋은 성과를 냈습니다.주가 변동성Is 688073's price volatile compared to industry and market?688073 volatility688073 Average Weekly Movement12.5%Pharmaceuticals Industry Average Movement6.8%Market Average Movement7.3%10% most volatile stocks in CN Market12.5%10% least volatile stocks in CN Market4.4%안정적인 주가: 688073의 주가는 지난 3개월 동안 CN 시장보다 변동성이 컸습니다.시간에 따른 변동성: 688073의 주간 변동성(13%)은 지난 1년 동안 안정적이었지만 CN 종목 중 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트2007734Lan Daiwww.bidepharm.com비데 파마텍은 중국에서 의약품의 연구, 개발, 생산 및 판매에 종사하고 있습니다. 이 회사의 제품은 생명 과학, 유기 화학, 재료 과학, 분석 화학 및 기타 응용 분야에 사용됩니다. 이 회사는 2007년에 설립되었으며 중국 상하이에 본사를 두고 있습니다.더 보기Bide Pharmatech Co., Ltd. 기초 지표 요약Bide Pharmatech의 순이익과 매출은 시가총액과 어떻게 비교됩니까?688073 기초 통계시가총액CN¥6.17b순이익 (TTM)CN¥167.88m매출 (TTM)CN¥1.35b36.7x주가수익비율(P/E)4.6x주가매출비율(P/S)688073는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표688073 손익계산서 (TTM)매출CN¥1.35b매출원가CN¥773.61m총이익CN¥577.11m기타 비용CN¥409.23m순이익CN¥167.88m최근 보고된 실적Mar 31, 2026다음 실적 발표일Aug 28, 2026주당순이익(EPS)1.95총이익률42.73%순이익률12.43%부채/자본 비율4.6%688073의 장기 실적은 어땠습니까?과거 실적 및 비교 보기배당1.6%현재 배당 수익률59%배당 성향View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/22 20:16종가2026/08/21 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Bide Pharmatech Co., Ltd.는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Yuan Yuan SunIndustrial Securities Co. Ltd.Hanyang HuangIndustrial Securities Co. Ltd.
Valuation Update With 7 Day Price Move • Aug 07Investor sentiment improves as stock rises 30%After last week's 30% share price gain to CN¥61.60, the stock trades at a trailing P/E ratio of 31.6x. Average trailing P/E is 33x in the Pharmaceuticals industry in China. Total returns to shareholders of 11% over the past year.
Valuation Update With 7 Day Price Move • Jul 15Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥57.43, the stock trades at a trailing P/E ratio of 29.5x. Average trailing P/E is 35x in the Pharmaceuticals industry in China. Total loss to shareholders of 1.8% over the past year.
공고 • Jun 30Bide Pharmatech Co., Ltd. to Report First Half, 2026 Results on Aug 28, 2026Bide Pharmatech Co., Ltd. announced that they will report first half, 2026 results on Aug 28, 2026
Valuation Update With 7 Day Price Move • Jun 29Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥54.24, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total loss to shareholders of 4.1% over the past year.
Declared Dividend • Jun 06Dividend of CN¥1.16 announcedShareholders will receive a dividend of CN¥1.16. Ex-date: 10th June 2026 Payment date: 10th June 2026 Dividend yield will be 2.4%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is covered by earnings (59% earnings payout ratio) but not covered by cash flows (281% cash payout ratio). The dividend has increased by an average of 1.8% per year over the past 3 years and payments have been stable during that time. EPS is expected to grow by 32% over the next year, which should provide support to the dividend and adequate earnings cover.
Board Change • May 20High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. R&D Director and Supervisor Ronghao Li is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Valuation Update With 7 Day Price Move • Aug 07Investor sentiment improves as stock rises 30%After last week's 30% share price gain to CN¥61.60, the stock trades at a trailing P/E ratio of 31.6x. Average trailing P/E is 33x in the Pharmaceuticals industry in China. Total returns to shareholders of 11% over the past year.
Valuation Update With 7 Day Price Move • Jul 15Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥57.43, the stock trades at a trailing P/E ratio of 29.5x. Average trailing P/E is 35x in the Pharmaceuticals industry in China. Total loss to shareholders of 1.8% over the past year.
공고 • Jun 30Bide Pharmatech Co., Ltd. to Report First Half, 2026 Results on Aug 28, 2026Bide Pharmatech Co., Ltd. announced that they will report first half, 2026 results on Aug 28, 2026
Valuation Update With 7 Day Price Move • Jun 29Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥54.24, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total loss to shareholders of 4.1% over the past year.
Declared Dividend • Jun 06Dividend of CN¥1.16 announcedShareholders will receive a dividend of CN¥1.16. Ex-date: 10th June 2026 Payment date: 10th June 2026 Dividend yield will be 2.4%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is covered by earnings (59% earnings payout ratio) but not covered by cash flows (281% cash payout ratio). The dividend has increased by an average of 1.8% per year over the past 3 years and payments have been stable during that time. EPS is expected to grow by 32% over the next year, which should provide support to the dividend and adequate earnings cover.
Board Change • May 20High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. R&D Director and Supervisor Ronghao Li is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공고 • Apr 23Bide Pharmatech Co., Ltd., Annual General Meeting, May 13, 2026Bide Pharmatech Co., Ltd., Annual General Meeting, May 13, 2026, at 09:30 China Standard Time. Location: 6F, Building 3, No. 999, Xiangyin Road, Yangpu District, Shanghai China
공고 • Mar 30Bide Pharmatech Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026Bide Pharmatech Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026
공고 • Dec 26Bide Pharmatech Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026Bide Pharmatech Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026
공고 • Sep 30Bide Pharmatech Co., Ltd. to Report Q3, 2025 Results on Oct 30, 2025Bide Pharmatech Co., Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025
공고 • Jun 30Bide Pharmatech Co., Ltd. to Report First Half, 2025 Results on Aug 22, 2025Bide Pharmatech Co., Ltd. announced that they will report first half, 2025 results on Aug 22, 2025
공고 • Apr 24Bide Pharmatech Co., Ltd., Annual General Meeting, May 14, 2025Bide Pharmatech Co., Ltd., Annual General Meeting, May 14, 2025, at 14:30 China Standard Time. Location: 6F, Building 3, No. 999, Xiangyin Road, Yangpu District, Shanghai China
공고 • Mar 28Bide Pharmatech Co., Ltd. to Report Q1, 2025 Results on Apr 24, 2025Bide Pharmatech Co., Ltd. announced that they will report Q1, 2025 results on Apr 24, 2025
공고 • Feb 10Bide Pharmatech Co., Ltd. (SHSE:688073) announces an Equity Buyback for CNY 100 million worth of its shares.Bide Pharmatech Co., Ltd. (SHSE:688073) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The shares will be purchased at a price not exceeding CNY 72.30 per share. The purpose of the program is to improve the company's long-term incentive mechanism, fully mobilize the enthusiasm of the employees, and jointly promote the company's long-term development. The repurchased shares will be used for employee stock ownership plans or equity incentive plans, otherwise will be cancelled if the company fails to transfer them within the time limit stipulated by relevant laws and regulations. The program will be funded from company's own funds and special loans. The program will be valid for 6 months.
공고 • Jan 22Bide Pharmatech Co., Ltd. (SHSE:688073) agreed to acquire an unknown minority stake in Zhuhai Weibo Investment Co., Ltd. from Vivo (Suzhou) Health Industry Investment Fund (Limited Partnership) managed by Vivo Capital, LLC and Vivo Equity Investment Management (Shanghai) Co. Ltd.Bide Pharmatech Co., Ltd. (SHSE:688073) agreed to acquire an unknown minority stake in Zhuhai Weibo Investment Co., Ltd. from Vivo (Suzhou) Health Industry Investment Fund (Limited Partnership) managed by Vivo Capital, LLC and Vivo Equity Investment Management (Shanghai) Co. Ltd. on January 21, 2025. The consideration consists of common equity of Bide Pharmatech Co., Ltd. to be issued for common equity of Zhuhai Weibo Investment Co., Ltd. As part of consideration, an undisclosed value is paid towards common equity of Zhuhai Weibo Investment Co., Ltd.
공고 • Dec 27Bide Pharmatech Co., Ltd. to Report Fiscal Year 2024 Results on Apr 24, 2025Bide Pharmatech Co., Ltd. announced that they will report fiscal year 2024 results on Apr 24, 2025
Valuation Update With 7 Day Price Move • Nov 05Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥42.00, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 18x in the Pharmaceuticals industry in China.
Reported Earnings • Oct 24Third quarter 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.33 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.36 (up from CN¥0.33 in 3Q 2023). Revenue: CN¥279.2m (down 1.1% from 3Q 2023). Net income: CN¥32.0m (up 8.2% from 3Q 2023). Profit margin: 12% (up from 11% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China.
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to CN¥33.82, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Simply Wall St's valuation model estimates the intrinsic value at CN¥44.40 per share.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 28%After last week's 28% share price gain to CN¥37.43, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Simply Wall St's valuation model estimates the intrinsic value at CN¥43.54 per share.
공고 • Sep 30Bide Pharmatech Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024Bide Pharmatech Co., Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024
Reported Earnings • Aug 29Second quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.51 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.29 (down from CN¥0.51 in 2Q 2023). Revenue: CN¥269.5m (flat on 2Q 2023). Net income: CN¥25.8m (down 45% from 2Q 2023). Profit margin: 9.6% (down from 17% in 2Q 2023). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China.
공고 • Jun 29Bide Pharmatech Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024Bide Pharmatech Co., Ltd. announced that they will report first half, 2024 results on Aug 29, 2024
공고 • May 15Bide Pharmatech Co., Ltd., Annual General Meeting, Jun 03, 2024Bide Pharmatech Co., Ltd., Annual General Meeting, Jun 03, 2024, at 14:30 China Standard Time. Location: 6F, Building 3, No. 999, Xiangyin Road, Yangpu District, Shanghai China
Reported Earnings • Apr 27First quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.41 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.29 (down from CN¥0.41 in 1Q 2023). Revenue: CN¥262.7m (up 4.0% from 1Q 2023). Net income: CN¥26.1m (down 29% from 1Q 2023). Profit margin: 9.9% (down from 15% in 1Q 2023). Revenue is forecast to grow 33% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China.
공고 • Mar 29Bide Pharmatech Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024Bide Pharmatech Co., Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024
Valuation Update With 7 Day Price Move • Mar 27Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥36.16, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 18x in the Pharmaceuticals industry in China.
Reported Earnings • Feb 03Full year 2023 earnings released: EPS: CN¥1.24 (vs CN¥1.98 in FY 2022)Full year 2023 results: EPS: CN¥1.24 (down from CN¥1.98 in FY 2022). Revenue: CN¥1.09b (up 31% from FY 2022). Net income: CN¥113.0m (down 23% from FY 2022). Profit margin: 10% (down from 18% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China.
Valuation Update With 7 Day Price Move • Feb 01Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to CN¥39.88, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 16x in the Pharmaceuticals industry in China.
공고 • Dec 30Bide Pharmatech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024Bide Pharmatech Co., Ltd. announced that they will report fiscal year 2023 results on Apr 26, 2024
Board Change • Nov 17Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Meng Zhang was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
